# A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

> **NCT07406542** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Recurrent or Metastatic Breast Cancer

## Interventions

- **DRUG:** SYS6010
- **DRUG:** Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine)

## Key facts

- **NCT ID:** NCT07406542
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406542, "A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07406542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*